8-K: SANUWAVE Health Achieves Record Preliminary Q2 2025 Revenue, Exceeding $10 Million

SANUWAVE Health, Inc. announced preliminary revenues for the second quarter of 2025 are expected to be between $10.1 million and $10.2 million, marking the highest Q2 revenue in company history and aligning with previous guidance.

Summary

• Preliminary revenues for the second quarter ended June 30, 2025, are projected to be in the range of $10.1 million to $10.2 million.
• This preliminary revenue figure represents the highest Q2 quarterly revenues in SANUWAVE Health's history.
• Q2 2025 revenue increased between 41% and 42% compared to Q2 2024.
• First half of 2025 revenue increased 50% to 51% compared to the first half of 2024.
• The preliminary revenue results are within the range of guidance provided in the company's Q1 2025 earnings release issued on May 9, 2025.
• The first half of 2025 has been a transition period, including the addition of a new head of sales and a new head of commercial operations.
• The company has been rapidly staffing up, expecting to reach 13 sales people in July, covering all national sales territories.
• A key national accounts manager has been added to pursue larger market opportunities.
• Full Q2 results are planned for release on or around August 8, 2025.

Sentiment

Score: 9

Explanation: The announcement is highly positive, reporting record preliminary Q2 revenues, significant year-over-year growth, and successful execution within guidance. Strategic hires and sales force expansion further reinforce a strong operational outlook and positive momentum.

Positives

• Achieved the highest Q2 quarterly revenues in company history, with preliminary revenues between $10.1 million and $10.2 million.
• Demonstrated strong year-over-year growth, with Q2 2025 revenue increasing 41% to 42% compared to Q2 2024.
• Reported significant first-half growth, with revenue increasing 50% to 51% compared to the first half of 2024.
• Successfully met the revenue guidance provided in the Q1 2025 earnings release.
• Expanded the sales team, reaching 13 sales people in July, ensuring all national sales territories are covered.
• Strengthened commercial operations with the addition of a new head of sales, a new head of commercial operations, and a dedicated national accounts manager.

Risks

• Preliminary revenue results are based on management's initial analysis and may be subject to adjustments upon completion of the quarter-end financial close process.
• Forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's control.
• Key risks include those associated with regulatory oversight, the company's ability to manage its capital resources, and competition.

Future Outlook

The company is excited about its pipeline and prospects for the current year and years ahead, following a successful transition period involving strategic staffing and commercial operations enhancements. Full Q2 results and a more complete update on quarterly performance and future guidance are expected around August 8, 2025.

Management Comments

• "We're pleased to once more be on guidance and on track for Q2 and for the first half of 2025."
• "The first half of 2025 has been a transition period for the company as we have added a new head of sales and now a new head of commercial operations."
• "Q2 was really the max transition period as we have been staffing up rapidly and will, in July, reach 13 sales people and for the first time in my tenure as CEO have all of our national sales territories covered."
• "We have also added a key national accounts manager to be our dedicated elephant hunter in order to better pursue some of the larger opportunities in our market."
• "This has been a period of taking the plane apart and putting it back together all while flying it quite fast, and the team has come through in phenomenal fashion."
• "We're all very excited about what we're building here, our pipeline, and the prospects for the year and years ahead."

Industry Context

SANUWAVE Health operates in the specialized and growing field of regenerative medicine and wound care, focusing on non-invasive medical systems. The reported strong revenue growth and strategic expansion of its sales force indicate a robust performance within this sector, suggesting effective market penetration and demand for its FDA-approved wound care products. The company's focus on energy transfer technologies for various medical conditions positions it within a niche but high-potential segment of the medical device industry.

Stakeholder Impact

• Shareholders: Likely positive impact due to record revenues, strong growth, and meeting financial guidance, potentially leading to increased share price.
• Employees: Positive impact due to rapid staffing up, expansion of sales team, and new key hires, indicating company growth and job security.
• Customers: Positive impact from expanded sales coverage and dedicated national accounts management, potentially leading to better service and access to products.

Next Steps

• Release full Q2 results on or around August 8, 2025.
• Provide a more complete update on quarterly performance and future plans and guidance during the full Q2 results release.

Key Dates

Recommendation

Keywords

SANUWAVE Health, SNWV, preliminary revenue, Q2 2025, financial results, wound care, medical devices, regenerative medicine, sales growth, NASDAQ